To assess the of GH-releasing
ABSTRACT
To assess the of GH-releasing effects of prolonged administration of a novel analog peptide (MK-6771, nine healthv voune men narticipated in a randomized, double blind, three-periodcros~over cbmparison of orally administered placebo and 5-and 25-mg doses of MK-677. Each period involved bedtime administration of the drug for 7 consecutive days. At the end of each period, plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) were measured at 0745 h, and 24-h profiles of plasma GH and cortisol were obtained at 15-min intervals together with the 24-h urinary excretion of free cortisol.
Profiles of plasma free cortisol were calculated at hourly intervals. The amounts of GH secreted were similar in all three conditions, but GH pulse frequency was increased with both dosages of the drug, primarily because of an increase in the number of low amplitude pulses. Plasma IGF-I levels were increased in a dose-dependent manner, whereas IGFBP-3 levels were increased only with the highest dosage. There was a positive relationship between GH pulse frequency and IGF-I increase. Except for an advance in the nocturnal nadir and in the morning elevation, MK-677 had no effect on cortisol profiles.
In particular, 24-h mean levels of plasma total and free cortisol and urinary excretion of free cortisol were similar under all conditions.
The present data suggest that the use of MK-677 for the treatment of relative somatotropic deficiency, particularly in older adults compromised by such deficiency, deserves further investigation.
(J Clin Endocrinol Metab 81: 2776-2782, 1996) G H IS RELEASED in a pulsatile fashion from the anterior pituitary under both positive and negative regulation by hypothalamic factors. GHRH stimulates GH secretion, whereas somatostatin exerts an inhibitory influence (1). The initiation of GH pulses could be due to GHRH pulses occurring during periods of low somatostatinergic tone (2).
During the past few years, a family of potent GH secretagogues, known as GH-releasing peptides (GHRPs), has been developed (3). The most studied of these compounds is GHRP-6. Although the mechanism of action of GHRP and related compounds is not completely elucidated, several lines of evidence suggest that specific receptors are involved at both the pituitary and the hypothalamic level (3). Current data support the concept that GHRP acts as a somatostatin antagonist via postreceptor mechanisms (4) and stimulates GH release synergistically with GHRH (5). In vitro, chronic exposure to GHRP or GHRH results in homologous desensitization, but does not inhibit the response to the alternate secretagogue (6, 7). In young adults, single doses of GHRP were shown to stimulate GH secretion in a dose-related manner (S), whereas continuous prolonged GHRP infusions enhanced pulsatile GH secretion and increased plasma insulin-like growth factor I (IGF-I) concentrations (9,10). Bolus injection of GHRP at the end of the infusion resulted in attenuated GH response, but bolus injection of GHRH under similar conditions was associated with an enhanced GH response, indicating that the prolonged infusion of GHRP resulted in a partial desensitization to this compound, rather than depletion of GH stores (9, 10). The effects of daily administration of GHRP and related compounds for prolonged periods of time remain to be assessed. GHRP has no effect on LH, FSH, TSH, insulin, or glucose concentrations (ll-13), but may increase cortisol and PRL levels (8, 13) .
Recently, novel compounds acting as functional agonists of the putative GHRP receptor have been synthesized and shown to have endocrine effects similar to those of GHRP (14-17). One of these compounds, MK-677 (also known as L-163,191), was found to be a potent GH secretagogue in vitro (17) and after administration of single doses in animals (17) and man (C. M. Mendel, personal communication). Unlike other GHRP-related molecules, MK-677 has excellent oral availability. The present placebo-controlled study was designed to examine in normal young men the effects of repeated administration for 7 consecutive days of two dosages of MK-677 on pulsatile GH secretion, IGF-I levels, and adrenocortical function. The drug was administered at bedtime to determine whether it would enhance the physiological release of GH that normally occurs after the onset of sleep. detectable GH pulses per 24 h averaged 11 -C 4 and 11 t 3, respectively, compared to 7 + 4 after placebo treatment (P < 0.02 for both dosages compared to placebo). This apparent higher pulse frequency resulted primarily from an increase in the number of low amplitude (peak GH levels <5 pg/L) pulses. Indeed, the frequency of large amplitude pulses was not affected by MK-677 treatment. Taking into account all individual profiles, a total of 16 pulses with a peak plasma value of 5 pg/L or more were observed with the placebo treatment VS. 18 pulses with the low dose and 16 pulses with the high dose of MK-677. This increase in the number of low amplitude pulses resulted in a significant elevation of the amount of GH secreted in the intervals between the large amplitude pulses (i.e. pulses with peak GH levels ~5 pg/L) after treatment with both the low (P < 0.04) and the high (P < 0.002) doses of MK-677 compared with placebo.
Subjects

Levels of serum IGF-I and IGFBPS
On day 1, before the treatment, serum levels of IGF-I (placebo, 279 -C 101 pg/L; low dose, 302 -C 97 pg/L; high dose, 255 t 98 pg/L) and IGFBP-3 (placebo, 2.48 ? 0.69 mg/L; low dose, 2.52 t 0.48 mg/L; high dose, 2.53 5 0.59 mg/L) were similar in the three studies. On day 8, serum levels of IGF-I were consistently higher after treatment with both doses of MK-677 than after placebo, as shown in the upper panel of Fig. 3 dropped from 326 pg/L with the low dose to 207 pg/L with the high dose of MK-677; hence, the difference in IGF-I between the low and the high dose fell outside the 99% confidence interval for all other subjects. If this outlier was excluded from the analysis, the increment in IGF-I values between the low and the high dose of MK-677 averaged 55 5 49 pg/L and was statistically significant (P < 0.03), indicating that MK-677 administration increased IGF-I levels in a dose-dependent manner. As illustrated in the lower panel of Fig. 3 , serum IGFBP-3 levels on day 8 were modestly, but significantly, higher after treatment with 25 mg MK-677 than after low dose or placebo treatment (P < 0.01). We investigated whether the elevation in IGF-I levels observed with both dosages of the MK-677 treatment could be related to the increase in GH pulse frequency. The correlation between the number of GH pulses on day 8 and the corresponding IGF-I level was significant after adjustment for each subject's mean level (r = 0.52; df = 16; P < 0.05).
Adrenocortical function
Mean profiles of plasma cortisol concentrations, calculated across subjects for each treatment condition, and individual profiles from one representative subject are shown in Fig. 4 . Group parameters quantifying cortisol secretion in each treatment condition are given in Table 2 . The 24-h mean levels of plasma cortisol, the values of the acrophase and the nadir, and the amplitude of the circadian variation were similar in all three conditions. However, after treatment with the high dose, but not the low dose, of MK-677, the timing of the nadir of the circadian cortisol variation was advanced by more than 1 h compared with that after placebo (P < 0.05). This advance of the nadir was associated with an earlier timing of the morning circadian rise (Fig. 4) . Despite the differences in the timing of the nadir and that of the morning rise, the timing of the acrophase was similar in the three treatment conditions. Similarly, the profiles of plasma CBG and albumin and that of the calculated plasma free cortisol were unaffected by treatment with MK-677. The 24-h cortisol secretion and urinary excretion of free cortisol were also similar in all three conditions. In contrast, serum DHEAS levels (which were similar in the three studies on day 1, before treatment) were higher on day 8 (P < 0.05) with both doses of MK-677 than with placebo (Table 2) . Differences in DHEAS values between the low and the high MK-677 dosages were not statistically significant.
Sleep
On day 8, after 7 days of treatment, the timing of sleep onset, the duration of the sleep period, the sleep efficiency, and the durations of stages wake, I plus II, and III were similar in the three study conditions. However, high dose treatment with MK-677 was associated with significant increases in the durations of stages IV (placebo, 37 t 19 min; high dose, 54 ? 29 min; P < 0.05) and REM (placebo, 85 5 19 min; high dose, 103 ? 10 min; P < 0.05).
Discussion
GH secretion decreases markedly with aging, so that the daily GH output in adults over 60 yr of age is typically less than one third of that in 20-to 30-yr-old subjects (28). The health consequences of reduced GH secretion include increased fat tissue and abdominal obesity, reduced muscle mass and strength, reduced exercise capacity, and reduced bone mineral content (29, 30) . Clinical trials with recombinant human GH have indicated that some of these effects of aging can be reversed by GH replacement (31-33). The development of orally active GH secretagogues able to enhance the endogenous pulsatile secretion of GH may constitute a more practical and physiological approach to the treatment of relative somatotropin deficiency than daily SC injections of recombinant human GH, which result in single and prolonged elevations of peripheral GH concentrations. The recent observations that acute administration of a newly developed mimic of GHRP consistently stimulates GH secretion in old (34) as well as in young (16) healthy subjects offer promise in that area. Whether increased GH secretion will persist after chronic, rather than acute, treatment with such compounds is unclear because chronic exposure to GHRP may result in homologous desensitization (9, lo), and it is not known whether GHRP stimulates de nova GH synthesis.
The present report describes for the first time the effects of repeated administration for 7 consecutive days of two dosages of a novel orally active mimic of GHRP, MK-677, in healthy young men. These dosages have been shown to elicit values after the higher dosage were significantly (P < 0.01) higher than those after placebo. Note that IGF-I levels were also significantly higher after the high dose than after the low dose (P < 0.03) if an outlier (subject 8, depicted by black triangles) was excluded from the analysis.
robust GH responses when given as single oral doses to normal young volunteers (C. M. Mendel, personal communication). In contrast, in the present study, the amounts of GH secreted and the temporal profile of GH secretion after 7 days of treatment with either the low or the high MK-677 dosage were similar to those observed after placebo treatment. However, the apparent frequency of GH pulses was increased with both dosages of the drug, primarily because of an increase in the number of detectable low amplitude pulses. This finding of an increased number of detectable GH pulses after treatment with MK-677 is consistent with the apparent enhancement of GH pulse frequency reported in a previous study during 24-h GHRP infusion (9). These observations could either represent a genuine drug-induced alteration of GH ultradian rhythmicity or reflect an enhancement of the amplitude of preexisting GH micropulses, undetectable by the immunoradiometric assays used in the present and previous (9) studies.
Despite similar values of GH secretion in the three experimental conditions, circulating levels of IGF-I were increased after 1 week of treatment with both dosages of MK-677. This could be due to the increase in the number and/or the amplitude of small GH pulses, resulting in elevated "basal" GH secretion. The finding of a relationship between GH pulse frequency and the increase in IGF-I values is consistent with this hypothesis. The feedback exerted by increased IGF-I levels on GH release is likely to explain the absence of global elevation of GH secretion. An alternative explanation could be that prolonged treatment with MK-677 induced a desensitization of somatotropic cells, and the increase in IGF-I levels without concomitant elevation of GH secretion resulted from the difference in the half-disappearance times of the two hormones (-15 min and -15 h, respectively) (35,36). However, a desensitization phenomenon appears unlikely, as it has recently been shown that the GH response to hexarelin, a synthetic hexapeptide similar to GHRP-6, is preserved after a 15-day treatment with this drug (37). Daily monitoring of serum IGF-I levels during a more prolonged administration of MK-677 and the use of an ultrasensitive chemiluminescence GH assay would probably allow elucidation of these questions. The elevation of IGFBP-3, which was observed only with the high MK-677 dosage, was more modest than that of IGF-I. This is consistent with data obtained in previous studies investigating the effects of GH administration in adults with and without GH deficiency, indicating that the magnitude of the IGF-I increase is markedly higher than the magnitude of the IGFBP-3 increase, especially when basal levels of IGF-I and IGFBP-3 are in the normal range (38, 39).
The 24-h mean levels of plasma total and free cortisol, the temporal pattern of cortisol secretion, and the 24-h urinary excretion of free cortisol were essentially unaffected by the treatment. The only significant effect observed with the higher dosage of MK-677 was an advance by approximately 1 h of the early morning cortisol rise, which could reflect an influence of the drug on the circadian regulation of corticotropic function and/or be related to its effects on sleep quality. Previous studies have shown that acute administration of GHRP or related compounds induces a short term stimulation of cortisol secretion (8,13). The relatively modest, but significant, increase in serum levels of DHEAS (a compound with a half-life of 8-11 h, US. 1.0-1.5 h for cortisol) (27, 40) could indicate that adrenocortical stimulation occurred during the first few days of treatment, but disappeared with prolonged administration. As recent data suggest that the well known decline of DHEAS with age could be an important component of the aging process (41), the ability of MK-677 to increase DHEAS levels could be beneficial in the elderly.
The durations of sleep stages IV and REM were significantly enhanced after treatment with the higher dosage of MK-677. Although the mechanisms involved in these sleeppromoting effects are not known, the present results are consistent with previously described somnogenic effects of GHRH and indicate that the hypnotic properties of MK-677 should be further examined in subjects with decreased sleep propensity.
In conclusion, daily oral administration for 1 week of MK-677, a novel GH secretagogue acting as a GHRP agonist, increases circulating IGF-I levels together with an apparent enhancement of GH pulse frequency, but without detectable elevation of GH secretion. This treatment does not induce any hypercortisolism. Furthermore, it is associated with an enhancement of both stage IV and REM sleep. Aging is characterized by a marked decrease in circulating IGF-I levels (42, 43), an increase in nighttime cortisol secretion (28), and profound alterations in sleep, including reductions in the amounts of the deeper stages of sleep as well as of REM sleep (28). Therefore, the present data suggest that the use of MK-677 for the treatment of relative GH deficiency and sleep disturbances in older adults deserves further investigation. in setting up the sleep laboratory and the sleep recording procedures.
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